Kidney biomarkers in cirrhosis

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 809-824

  Francoz, Claire ^a,b,c,d   Nadim, Mitra K ^e   Durand, François ^a,b,c,d  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^d Service d Hépatologie   (France)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute kidney injury (AKI); Biomarkers; Chronic kidney disease (CKD); Cirrhosis; Renal dysfunction

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALBINDIN; CLUSTERIN; CYSTATIN C; FATTY ACID BINDING PROTEIN; INTERLEUKIN 18; INTESTINAL TREFOIL FACTOR; KIDNEY INJURY MOLECULE 1; LIVER TYPE FATTY ACID BINDING PROTEIN; MICRORNA; MICRORNA 148B; MICRORNA 223; MICRORNA 433; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NITROGEN; NORADRENALIN; OSTEOPONTIN; TERLIPRESSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TREFOIL FACTOR 3 PROTEIN; UNCLASSIFIED DRUG; UREA; CREATININE;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; CHRONIC KIDNEY DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE MARKER; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; GOLD STANDARD; HEPATORENAL SYNDROME; HUMAN; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TYPE 1 HEPATORENAL SYNDROME; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; KIDNEY;

ACUTE KIDNEY INJURY; BIOMARKERS; CREATININE; HUMANS; KIDNEY; LIPOCALIN-2; LIVER CIRRHOSIS;

EID: 84991730154     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.025     Document Type: Review

References (168)

1. [1] Kamath, P.S., Wiesner, R.H., Malinchoc, M., Kremers, W., Therneau, T.M., Kosberg, C.L., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 (2001), 464–470.
2. [2] Durand, F., Valla, D., Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 42 (2005), S100–S107.
3. [3] Arroyo, V., Gines, P., Gerbes, A.L., Dudley, F.J., Gentilini, P., Laffi, G., et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 23 (1996), 164–176.
4. [4] Moreau, R., Lebrec, D., Acute renal failure in patients with cirrhosis: perspectives in the age of MELD. Hepatology 37 (2003), 233–243.
5. [5] Schrier, R.W., Arroyo, V., Bernardi, M., Epstein, M., Henriksen, J.H., Rodes, J., Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8 (1988), 1151–1157.
6. [6] Durand, F., Graupera, I., Gines, P., Olson, J.C., Nadim, M.K., Pathogenesis of hepatorenal syndrome: implications for therapy. Am J Kidney Dis, 2015.
7. [7] Gines, P., Schrier, R.W., Renal failure in cirrhosis. N Engl J Med 361 (2009), 1279–1290.
8. [8] Krag, A., Bendtsen, F., Henriksen, J.H., Moller, S., Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 59 (2010), 105–110.
9. [9] Planas, R., Arroyo, V., Rimola, A., Perez-Ayuso, R.M., Rodes, J., Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 84 (1983), 247–252.
10. [10] Elia, C., Graupera, I., Barreto, R., Sola, E., Moreira, R., Huelin, P., et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. J Hepatol 63 (2015), 593–600.
11. [11] Stadlbauer, V., Wright, G.A., Banaji, M., Mukhopadhya, A., Mookerjee, R.P., Moore, K., et al. Relationship between activation of the sympathetic nervous system and renal blood flow autoregulation in cirrhosis. Gastroenterology 134 (2008), 111–119.
12. [12] Bernardi, M., Moreau, R., Angeli, P., Schnabl, B., Arroyo, V., Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 63 (2015), 1272–1284.
13. [13] Alobaidi, R., Basu, R.K., Goldstein, S.L., Bagshaw, S.M., Sepsis-associated acute kidney injury. Semin Nephrol 35 (2015), 2–11.
14. [14] Prowle, J.R., Bellomo, R., Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation. Semin Nephrol 35 (2015), 64–74.
15. [15] Langenberg, C., Wan, L., Egi, M., May, C.N., Bellomo, R., Renal blood flow and function during recovery from experimental septic acute kidney injury. Intensive Care Med 33 (2007), 1614–1618.
16. [16] Langenberg, C., Wan, L., Egi, M., May, C.N., Bellomo, R., Renal blood flow in experimental septic acute renal failure. Kidney Int 69 (2006), 1996–2002.
17. [17] Wiest, R., Lawson, M., Geuking, M., Pathological bacterial translocation in liver cirrhosis. J Hepatol 60 (2014), 197–209.
18. [18] Albillos, A., de la Hera, A., Gonzalez, M., Moya, J.L., Calleja, J.L., Monserrat, J., et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37 (2003), 208–217.
19. [19] Thabut, D., Massard, J., Gangloff, A., Carbonell, N., Francoz, C., Nguyen-Khac, E., et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology 46 (2007), 1872–1882.
20. [20] Shah, N., Dhar, D., El Zahraa, Mohammed F., Habtesion, A., Davies, N.A., Jover-Cobos, M., et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J Hepatol 56 (2012), 1047–1053.
21. [21] Shah, N., Mohamed, F.E., Jover-Cobos, M., Macnaughtan, J., Davies, N., Moreau, R., et al. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosis. Liver Int 33 (2013), 398–409.
22. [22] Kanel, G.C., Peters, R.L., Glomerular tubular reflux–a morphologic renal lesion associated with the hepatorenal syndrome. Hepatology 4 (1984), 242–246.
23. [23] Mandal, A.K., Lansing, M., Fahmy, A., Acute tubular necrosis in hepatorenal syndrome: an electron microscopy study. Am J Kidney Dis 2 (1982), 363–374.
24. [24] Wolfs, T.G., Buurman, W.A., van Schadewijk, A., de Vries, B., Daemen, M.A., Hiemstra, P.S., et al. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 168 (2002), 1286–1293.
25. [25] van Kooten, C., Woltman, A.M., Daha, M.R., Immunological function of tubular epithelial cells: the functional implications of CD40 expression. Exp Nephrol 8 (2000), 203–207.
26. [26] Emlet, D.R., Shaw, A.D., Kellum, J.A., Sepsis-associated AKI: epithelial cell dysfunction. Semin Nephrol 35 (2015), 85–95.
27. [27] Vaidya, V.S., Waikar, S.S., Ferguson, M.A., Collings, F.B., Sunderland, K., Gioules, C., et al. Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci 1 (2008), 200–208.
28. [28] Francoz, C., Glotz, D., Moreau, R., Durand, F., The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 52 (2010), 605–613.
29. [29] Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
30. [30] Trawale, J.M., Paradis, V., Rautou, P.E., Francoz, C., Escolano, S., Sallee, M., et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 30 (2010), 725–732.
31. [31] Calmus, Y., Conti, F., Cluzel, P., Hill, G., Antoine, C., Scatton, O., et al. Prospective assessment of renal histopathological lesions in patients with end-stage liver disease: effects on long-term renal function after liver transplantation. J Hepatol 57 (2012), 572–576.
32. [32] Gloviczki, M.L., Keddis, M.T., Garovic, V.D., Friedman, H., Herrmann, S., McKusick, M.A., et al. TGF expression and macrophage accumulation in atherosclerotic renal artery stenosis. Clin J Am Soc Nephrol 8 (2013), 546–553.
33. [33] Keddis, M.T., Garovic, V.D., Bailey, K.R., Wood, C.M., Raissian, Y., Grande, J.P., Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. Nephrol Dial Transplant 25 (2010), 3615–3622.
34. [34] Chawla, L.S., Eggers, P.W., Star, R.A., Kimmel, P.L., Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 371 (2014), 58–66.
35. [35] Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976), 31–41.
36. [36] Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N., Roth, D., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130 (1999), 461–470.
37. [37] Sherman, D.S., Fish, D.N., Teitelbaum, I., Assessing renal function in cirrhotic patients: problems and pitfalls. Am J Kidney Dis 41 (2003), 269–278.
38. [38] Francoz, C., Prie, D., Abdelrazek, W., Moreau, R., Mandot, A., Belghiti, J., et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 16 (2010), 1169–1177.
39. [39] Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F. 3rd, Feldman, H.I., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
40. [40] Gonwa, T.A., Jennings, L., Mai, M.L., Stark, P.C., Levey, A.S., Klintmalm, G.B., Estimation of glomerular filtration rates before and after orthotopic liver transplantation: evaluation of current equations. Liver Transpl 10 (2004), 301–309.
41. [41] Francoz, C., Nadim, M.K., Baron, A., Prie, D., Antoine, C., Belghiti, J., et al. Glomerular filtration rate equations for liver-kidney transplantation in patients with cirrhosis: validation of current recommendations. Hepatology 59 (2014), 1514–1521.
42. [42] Nadim, M.K., Sung, R.S., Davis, C.L., Andreoni, K.A., Biggins, S.W., Danovitch, G.M., et al. Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant 12 (2012), 2901–2908.
43. [43] Herget-Rosenthal, S., Trabold, S., Pietruck, F., Holtmann, M., Philipp, T., Kribben, A., Cystatin C: efficacy as screening test for reduced glomerular filtration rate. Am J Nephrol 20 (2000), 97–102.
44. [44] Cholongitas, E., Shusang, V., Marelli, L., Nair, D., Thomas, M., Patch, D., et al. Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther 26 (2007), 969–978.
45. [45] Gerbes, A.L., Gulberg, V., Bilzer, M., Vogeser, M., Evaluation of serum cystatin C concentration as a marker of renal function in patients with cirrhosis of the liver. Gut 50 (2002), 106–110.
46. [46] Inker, L.A., Schmid, C.H., Tighiouart, H., Eckfeldt, J.H., Feldman, H.I., Greene, T., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 367 (2012), 20–29.
47. [47] Levey, A.S., Becker, C., Inker, L.A., Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. JAMA 313 (2015), 837–846.
48. [48] Levin, A., Stevens, P.E., WITHDRAWN: Summary of KDIGO guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int, 2013.
49. [49] Delanaye, P., Mariat, C., The applicability of eGFR equations to different populations. Nat Rev Nephrol 9 (2013), 513–522.
50. [50] Schaeffner, E.S., Ebert, N., Delanaye, P., Frei, U., Gaedeke, J., Jakob, O., et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 157 (2012), 471–481.
51. [51] Shlipak, M.G., Coresh, J., Gansevoort, R.T., Cystatin C versus creatinine for kidney function-based risk. N Engl J Med, 369, 2013, 2459.
52. [52] Mindikoglu, A.L., Dowling, T.C., Weir, M.R., Seliger, S.L., Christenson, R.H., Magder, L.S., Performance of chronic kidney disease epidemiology collaboration creatinine-cystatin C equation for estimating kidney function in cirrhosis. Hepatology 59 (2014), 1532–1542.
53. [53] De Souza, V., Hadj-Aissa, A., Dolomanova, O., Rabilloud, M., Rognant, N., Lemoine, S., et al. Creatinine- versus cystatine C-based equations in assessing the renal function of candidates for liver transplantation with cirrhosis. Hepatology 59 (2014), 1522–1531.
54. [54] Bianchi, C., Donadio, C., Tramonti, G., Consani, C., Lorusso, P., Rossi, G., Reappraisal of serum beta2-microglobulin as marker of GFR. Ren Fail 23 (2001), 419–429.
55. [55] Shinkai, S., Chaves, P.H., Fujiwara, Y., Watanabe, S., Shibata, H., Yoshida, H., et al. Beta2-microglobulin for risk stratification of total mortality in the elderly population: comparison with cystatin C and C-reactive protein. Arch Intern Med 168 (2008), 200–206.
56. [56] Cardenas, A., Gines, P., Uriz, J., Bessa, X., Salmeron, J.M., Mas, A., et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 34 (2001), 671–676.
57. [57] Fasolato, S., Angeli, P., Dallagnese, L., Maresio, G., Zola, E., Mazza, E., et al. Renal failure and bacterial infections in patients with cirrhosis: epidemiology and clinical features. Hepatology 45 (2007), 223–229.
58. [58] Terra, C., Guevara, M., Torre, A., Gilabert, R., Fernandez, J., Martin-Llahi, M., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 129 (2005), 1944–1953.
59. [59] Bellomo, R., Ronco, C., Kellum, J.A., Mehta, R.L., Palevsky, P., Acute Dialysis Quality Initiative workgroup. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004), R204–R212.
60. [60] Mehta, R.L., Kellum, J.A., Shah, S.V., Molitoris, B.A., Ronco, C., Warnock, D.G., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care, 11, 2007, R31.
61. [61] Wong, F., Leung, W., Al Beshir, M., Marquez, M., Renner, E.L., Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation. Liver Transpl 21 (2015), 300–307.
62. [62] Hoste, E.A., Clermont, G., Kersten, A., Venkataraman, R., Angus, D.C., De Bacquer, D., et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care, 10, 2006, R73.
63. [63] Leite, T.T., Macedo, E., Pereira, S.M., Bandeira, S.R., Pontes, P.H., Garcia, A.S., et al. Timing of renal replacement therapy initiation by AKIN classification system. Crit Care, 17, 2013, R62.
64. [64] Belcher, J.M., Garcia-Tsao, G., Sanyal, A.J., Bhogal, H., Lim, J.K., Ansari, N., et al. Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology 57 (2013), 753–762.
65. [65] Wong, F., O'Leary, J.G., Reddy, K.R., Patton, H., Kamath, P.S., Fallon, M.B., et al. New consensus definition of acute kidney injury accurately predicts 30-day mortality in patients with cirrhosis and infection. Gastroenterology 145 (2013), 1280–1288, e1281.
66. [66] Angeli, P., Gines, P., Wong, F., Bernardi, M., Boyer, T.D., Gerbes, A., et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 62 (2015), 968–974.
67. [67] Garcia-Tsao, G., Parikh, C.R., Viola, A., Acute kidney injury in cirrhosis. Hepatology 48 (2008), 2064–2077.
68. [68] Kashani, K., Kellum, J.A., Novel biomarkers indicating repair or progression after acute kidney injury. Curr Opin Nephrol Hypertens 24 (2015), 21–27.
69. [69] Belcher, J.M., Acute Kidney Injury in Liver Disease: Role of Biomarkers. Adv Chronic Kidney Dis 22 (2015), 368–375.
70. [70] Adebayo, D., Morabito, V., Davenport, A., Jalan, R., Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int 87 (2015), 509–515.
71. [71] Wong, F., The evolving concept of acute kidney injury in patients with cirrhosis. Nat Rev Gastroenterol Hepatol 12 (2015), 711–719.
72. [72] Moreau, R., Durand, F., Poynard, T., Duhamel, C., Cervoni, J.P., Ichai, P., et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 122 (2002), 923–930.
73. [73] Sharma, P., Kumar, A., Shrama, B.C., Sarin, S.K., An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol 103 (2008), 1689–1697.
74. [74] Sanyal, A.J., Boyer, T., Garcia-Tsao, G., Regenstein, F., Rossaro, L., Appenrodt, B., et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134 (2008), 1360–1368.
75. [75] Boyer, T.D., Sanyal, A.J., Garcia-Tsao, G., Regenstein, F., Rossaro, L., Appenrodt, B., et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl 17 (2011), 1328–1332.
76. [76] Ruiz, R., Barri, Y.M., Jennings, L.W., Chinnakotla, S., Goldstein, R.M., Levy, M.F., et al. Hepatorenal syndrome: a proposal for kidney after liver transplantation (KALT). Liver Transpl 13 (2007), 838–843.
77. [77] Gonwa, T.A., Klintmalm, G.B., Levy, M., Jennings, L.S., Goldstein, R.M., Husberg, B.S., Impact of pretransplant renal function on survival after liver transplantation. Transplantation 59 (1995), 361–365.
78. [78] Riphagen, I.J., Deetman, P.E., Bakker, S.J., Navis, G., Cooper, M.E., Lewis, J.B., et al. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. Diabetes 63 (2014), 2845–2853.
79. [79] Lee, A.T., Wang, Y.Y., Lin, S.Y., Liang, J.T., Sheu, W.H., Song, Y.M., et al. Higher serum total bilirubin concentration is associated with lower risk of renal insufficiency in an adult population. Int J Clin Exp Med 8 (2015), 19212–19222.
80. [80] Boon, A.C., Lam, A.K., Gopalan, V., Benzie, I.F., Briskey, D., Coombes, J.S., et al. Endogenously elevated bilirubin modulates kidney function and protects from circulating oxidative stress in a rat model of adenine-induced kidney failure. Sci Rep, 5, 2015, 15482.
81. [81] Pepin, M.N., Bouchard, J., Legault, L., Ethier, J., Diagnostic performance of fractional excretion of urea and fractional excretion of sodium in the evaluations of patients with acute kidney injury with or without diuretic treatment. Am J Kidney Dis 50 (2007), 566–573.
82. [82] Cabrera, J., Arroyo, V., Ballesta, A.M., Rimola, A., Gual, J., Elena, M., et al. Aminoglycoside nephrotoxicity in cirrhosis. Value of urinary beta 2-microglobulin to discriminate functional renal failure from acute tubular damage. Gastroenterology 82 (1982), 97–105.
83. [83] Belcher, J.M., Garcia-Tsao, G., Sanyal, A.J., Thiessen-Philbrook, H., Peixoto, A.J., Perazella, M.A., et al. Urinary biomarkers and progression of AKI in patients with cirrhosis. Clin J Am Soc Nephrol 9 (2014), 1857–1867.
84. [84] Carvounis, C.P., Nisar, S., Guro-Razuman, S., Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int 62 (2002), 2223–2229.
85. [85] Stevens, P.E., Levin, A., Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group M. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes: clinical practice guideline. Ann Intern Med 2013 (2012), 825–830.
86. [86] Perazella, M.A., Coca, S.G., Kanbay, M., Brewster, U.C., Parikh, C.R., Diagnostic value of urine microscopy for differential diagnosis of acute kidney injury in hospitalized patients. Clin J Am Soc Nephrol 3 (2008), 1615–1619.
87. [87] Wadei, H.M., Geiger, X.J., Cortese, C., Mai, M.L., Kramer, D.J., Rosser, B.G., et al. Kidney allocation to liver transplant candidates with renal failure of undetermined etiology: role of percutaneous renal biopsy. Am J Transplant 8 (2008), 2618–2626.
88. [88] Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14 (2003), 2534–2543.
89. [89] Mishra, J., Mori, K., Ma, Q., Kelly, C., Yang, J., Mitsnefes, M., et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 15 (2004), 3073–3082.
90. [90] Wheeler, D.S., Devarajan, P., Ma, Q., Harmon, K., Monaco, M., Cvijanovich, N., et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med 36 (2008), 1297–1303.
91. [91] Hirsch, R., Dent, C., Pfriem, H., Allen, J., Beekman, R.H. 3rd, Ma, Q., et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 22 (2007), 2089–2095.
92. [92] Mishra, J., Dent, C., Tarabishi, R., Mitsnefes, M.M., Ma, Q., Kelly, C., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365 (2005), 1231–1238.
93. [93] Wagener, G., Jan, M., Kim, M., Mori, K., Barasch, J.M., Sladen, R.N., et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105 (2006), 485–491.
94. [94] Makris, K., Markou, N., Evodia, E., Dimopoulou, E., Drakopoulos, I., Ntetsika, K., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 47 (2009), 79–82.
95. [95] Trachtman, H., Christen, E., Cnaan, A., Patrick, J., Mai, V., Mishra, J., et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 21 (2006), 989–994.
96. [96] Nickolas, T.L., O'Rourke, M.J., Yang, J., Sise, M.E., Canetta, P.A., Barasch, N., et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 148 (2008), 810–819.
97. [97] Pianta, T.J., Peake, P.W., Pickering, J.W., Kelleher, M., Buckley, N.A., Endre, Z.H., Clusterin in kidney transplantation: novel biomarkers versus serum creatinine for early prediction of delayed graft function. Transplantation 99 (2015), 171–179.
98. [98] Lee, E.Y., Kim, M.S., Park, Y., Kim, H.S., Serum neutrophil gelatinase-associated lipocalin and interleukin-18 as predictive biomarkers for delayed graft function after kidney transplantation. J Clin Lab Anal 26 (2012), 295–301.
99. [99] Kohei, J., Ishida, H., Tanabe, K., Tsuchiya, K., Nitta, K., Neutrophil gelatinase-associated lipocalin is a sensitive biomarker for the early diagnosis of acute rejection after living-donor kidney transplantation. Int Urol Nephrol 45 (2013), 1159–1167.
100. [100] Torres-Salido, M.T., Cortes-Hernandez, J., Vidal, X., Pedrosa, A., Vilardell-Tarres, M., Ordi-Ros, J., Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. Nephrol Dial Transplant 29 (2014), 1740–1749.
101. [101] Ding, H., He, Y., Li, K., Yang, J., Li, X., Lu, R., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol 123 (2007), 227–234.
102. [102] Barreto, R., Elia, C., Sola, E., Moreira, R., Ariza, X., Rodriguez, E., et al. Urinary neutrophil gelatinase-associated lipocalin predicts kidney outcome and death in patients with cirrhosis and bacterial infections. J Hepatol 61 (2014), 35–42.
103. [103] Belcher, J.M., Sanyal, A.J., Peixoto, A.J., Perazella, M.A., Lim, J., Thiessen-Philbrook, H., et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 60 (2014), 622–632.
104. [104] Fagundes, C., Pepin, M.N., Guevara, M., Barreto, R., Casals, G., Sola, E., et al. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J Hepatol 57 (2012), 267–273.
105. [105] Verna, E.C., Brown, R.S., Farrand, E., Pichardo, E.M., Forster, C.S., Sola-Del Valle, D.A., et al. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig Dis Sci 57 (2012), 2362–2370.
106. [106] Ostermann, M., Joannidis, M., Biomarkers for AKI improve clinical practice: no. Intensive Care Med 41 (2015), 618–622.
107. [107] Martensson, J., Bellomo, R., The rise and fall of NGAL in acute kidney injury. Blood Purif 37 (2014), 304–310.
108. [108] Macdonald, S.P., Stone, S.F., Neil, C.L., van Eeden, P.E., Fatovich, D.M., Arendts, G., et al. Sustained elevation of resistin, NGAL and IL-8 are associated with severe sepsis/septic shock in the emergency department. PLoS One, 9, 2014, e110678.
109. [109] Otto, G.P., Busch, M., Sossdorf, M., Claus, R.A., Impact of sepsis-associated cytokine storm on plasma NGAL during acute kidney injury in a model of polymicrobial sepsis. Crit Care, 17, 2013, 419.
110. [110] Ariza, X., Sola, E., Elia, C., Barreto, R., Moreira, R., Morales-Ruiz, M., et al. Analysis of a urinary biomarker panel for clinical outcomes assessment in cirrhosis. PLoS One, 10, 2015, e0128145.
111. [111] Liu, Y., Guo, W., Zhang, J., Xu, C., Yu, S., Mao, Z., et al. Urinary interleukin 18 for detection of acute kidney injury: a meta-analysis. Am J Kidney Dis 62 (2013), 1058–1067.
112. [112] Wu, H., Craft, M.L., Wang, P., Wyburn, K.R., Chen, G., Ma, J., et al. IL-18 contributes to renal damage after ischemia-reperfusion. J Am Soc Nephrol 19 (2008), 2331–2341.
113. [113] Siew, E.D., Ikizler, T.A., Gebretsadik, T., Shintani, A., Wickersham, N., Bossert, F., et al. Elevated urinary IL-18 levels at the time of ICU admission predict adverse clinical outcomes. Clin J Am Soc Nephrol 5 (2010), 1497–1505.
114. [114] Ichimura, T., Bonventre, J.V., Bailly, V., Wei, H., Hession, C.A., Cate, R.L., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273 (1998), 4135–4142.
115. [115] Han, W.K., Bailly, V., Abichandani, R., Thadhani, R., Bonventre, J.V., Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62 (2002), 237–244.
116. [116] Nishida, M., Kawakatsu, H., Okumura, Y., Hamaoka, K., Serum and urinary neutrophil gelatinase-associated lipocalin levels in children with chronic renal diseases. Pediatr Int 52 (2010), 563–568.
117. [117] Parikh, C.R., Devarajan, P., New biomarkers of acute kidney injury. Crit Care Med 36 (2008), S159–S165.
118. [118] Qasem, A.A., Farag, S.E., Hamed, E., Emara, M., Bihery, A., Pasha, H., Urinary biomarkers of acute kidney injury in patients with liver cirrhosis. ISRN Nephrol, 2014, 2014, 376795.
119. [119] Furuhashi, M., Hotamisligil, G.S., Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 7 (2008), 489–503.
120. [120] Kamijo-Ikemori, A., Sugaya, T., Matsui, K., Yokoyama, T., Kimura, K., Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology (Carlton) 16 (2011), 539–544.
121. [121] Yokoyama, T., Kamijo-Ikemori, A., Sugaya, T., Hoshino, S., Yasuda, T., Kimura, K., Urinary excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 174 (2009), 2096–2106.
122. [122] Doi, K., Noiri, E., Maeda-Mamiya, R., Ishii, T., Negishi, K., Hamasaki, Y., et al. Urinary L-type fatty acid-binding protein as a new biomarker of sepsis complicated with acute kidney injury. Crit Care Med 38 (2010), 2037–2042.
123. [123] Yamamoto, T., Noiri, E., Ono, Y., Doi, K., Negishi, K., Kamijo, A., et al. Renal L-type fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 18 (2007), 2894–2902.
124. [124] Xu, Y., Xie, Y., Shao, X., Ni, Z., Mou, S., L-FABP: A novel biomarker of kidney disease. Clin Chim Acta 445 (2015), 85–90.
125. [125] Haase-Fielitz, A., Bellomo, R., Devarajan, P., Story, D., Matalanis, G., Dragun, D., et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery–a prospective cohort study. Crit Care Med 37 (2009), 553–560.
126. [126] Herget-Rosenthal, S., Marggraf, G., Husing, J., Goring, F., Pietruck, F., Janssen, O., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 66 (2004), 1115–1122.
127. [127] Nejat, M., Pickering, J.W., Walker, R.J., Endre, Z.H., Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. Nephrol Dial Transplant 25 (2010), 3283–3289.
128. [128] Zappitelli, M., Krawczeski, C.D., Devarajan, P., Wang, Z., Sint, K., Thiessen-Philbrook, H., et al. Early postoperative serum cystatin C predicts severe acute kidney injury following pediatric cardiac surgery. Kidney Int 80 (2011), 655–662.
129. [129] Belcher, J.M., Sanyal, A.J., Garcia-Tsao, G., Ansari, N., Coca, S.G., Shlipak, M.G., et al. Early trends in cystatin C and outcomes in patients with cirrhosis and acute kidney injury. Int J Nephrol, 2014, 2014, 708585.
130. [130] Slack, A.J., McPhail, M.J., Ostermann, M., Bruce, M., Sherwood, R., Musto, R., et al. Predicting the development of acute kidney injury in liver cirrhosis–an analysis of glomerular filtration rate, proteinuria and kidney injury biomarkers. Aliment Pharmacol Ther 37 (2013), 989–997.
131. [131] Lorenzen, J.M., Hafer, C., Faulhaber-Walter, R., Kumpers, P., Kielstein, J.T., Haller, H., et al. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol Dial Transplant 26 (2011), 531–537.
132. [132] Nejat, M., Pickering, J.W., Walker, R.J., Westhuyzen, J., Shaw, G.M., Frampton, C.M., et al. Urinary cystatin C is diagnostic of acute kidney injury and sepsis, and predicts mortality in the intensive care unit. Crit Care, 14, 2010, R85.
133. [133] Verstrepen, W.A., Persy, V.P., Verhulst, A., Dauwe, S., De Broe, M.E., Renal osteopontin protein and mRNA upregulation during acute nephrotoxicity in the rat. Nephrol Dial Transplant 16 (2001), 712–724.
134. [134] Levitsky, J., Baker, T.B., Jie, C., Ahya, S., Levin, M., Friedewald, J., et al. Plasma protein biomarkers enhance the clinical prediction of kidney injury recovery in patients undergoing liver transplantation. Hepatology 60 (2014), 2017–2026.
135. [135] Anders, H.J., Banas, B., Schlondorff, D., Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15 (2004), 854–867.
136. [136] Jouet, P., Meyrier, A., Mal, F., Callard, P., Guettier, C., Stordeur, D., et al. Transjugular renal biopsy in the treatment of patients with cirrhosis and renal abnormalities. Hepatology 24 (1996), 1143–1147.
137. [137] Mal, F., Meyrier, A., Callard, P., Kleinknecht, D., Altmann, J.J., Beaugrand, M., The diagnostic yield of transjugular renal biopsy. Experience in 200 cases. Kidney Int 41 (1992), 445–449.
138. [138] Eason, J.D., Gonwa, T.A., Davis, C.L., Sung, R.S., Gerber, D., Bloom, R.D., Proceedings of Consensus Conference on Simultaneous Liver Kidney Transplantation (SLK). Am J Transplant 8 (2008), 2243–2251.
139. [139] Xu, T.Y., Zhang, Y., Li, Y., Zhu, D.L., Gao, P.J., The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients. Ren Fail 36 (2014), 666–672.
140. [140] Ambros, V., The functions of animal microRNAs. Nature 431 (2004), 350–355.
141. [141] Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004), 281–297.
142. [142] Carrington, J.C., Ambros, V., Role of microRNAs in plant and animal development. Science 301 (2003), 336–338.
143. [143] Lorenzen, J.M., Thum, T., Circulating and urinary microRNAs in kidney disease. Clin J Am Soc Nephrol 7 (2012), 1528–1533.
144. [144] Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 129 (2007), 1401–1414.
145. [145] Sun, Y., Koo, S., White, N., Peralta, E., Esau, C., Dean, N.M., et al. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res, 32, 2004, e188.
146. [146] Chandrasekaran, K., Karolina, D.S., Sepramaniam, S., Armugam, A., Wintour, E.M., Bertram, J.F., et al. Role of microRNAs in kidney homeostasis and disease. Kidney Int 81 (2012), 617–627.
147. [147] Trionfini, P., Benigni, A., Remuzzi, G., MicroRNAs in kidney physiology and disease. Nat Rev Nephrol 11 (2015), 23–33.
148. [148] Boor, P., Floege, J., Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 38 (2011), 441–450.
149. [149] Chung, A.C., Lan, H.Y., MicroRNAs in renal fibrosis. Front Physiol, 6, 2015, 50.
150. [150] Lan, H.Y., Chung, A.C., TGF-beta/Smad signaling in kidney disease. Semin Nephrol 32 (2012), 236–243.
151. [151] Serino, G., Sallustio, F., Cox, S.N., Pesce, F., Schena, F.P., Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol 23 (2012), 814–824.
152. [152] Bao, H., Chen, H., Zhu, X., Zhang, M., Yao, G., Yu, Y., et al. MiR-223 downregulation promotes glomerular endothelial cell activation by upregulating importin alpha4 and alpha5 in IgA nephropathy. Kidney Int 85 (2014), 624–635.
153. [153] Hayek, S.S., Sever, S., Ko, Y.A., Trachtman, H., Awad, M., Wadhwani, S., et al. Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med 373 (2015), 1916–1925.
154. [154] Levey, A.S., Coresh, J., Chronic kidney disease. Lancet 379 (2012), 165–180.
155. [155] Chawla, L.S., Amdur, R.L., Amodeo, S., Kimmel, P.L., Palant, C.E., The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int 79 (2011), 1361–1369.
156. [156] Khosla, N., Soroko, S.B., Chertow, G.M., Himmelfarb, J., Ikizler, T.A., Paganini, E., et al. Preexisting chronic kidney disease: a potential for improved outcomes from acute kidney injury. Clin J Am Soc Nephrol 4 (2009), 1914–1919.
157. [157] Bonventre, J.V., Maladaptive proximal tubule repair: cell cycle arrest. Nephron Clin Pract 127 (2014), 61–64.
158. [158] Ferenbach, D.A., Bonventre, J.V., Mechanisms of maladaptive repair after AKI leading to accelerated kidney ageing and CKD. Nat Rev Nephrol 11 (2015), 264–276.
159. [159] Thadhani, R., Pascual, M., Bonventre, J.V., Acute renal failure. N Engl J Med 334 (1996), 1448–1460.
160. [160] Bonventre, J.V., Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure. J Am Soc Nephrol 14 (2003), S55–S61.
161. [161] Cantley, L.G., Adult stem cells in the repair of the injured renal tubule. Nat Clin Pract Nephrol 1 (2005), 22–32.
162. [162] Hoek, F.J., Kemperman, F.A., Krediet, R.T., A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18 (2003), 2024–2031.
163. [163] Levitsky, J., Baker, T., Ahya, S.N., Levin, M.L., Friedewald, J., Gallon, L., et al. Outcomes and native renal recovery following simultaneous liver-kidney transplantation. Am J Transplant 12 (2012), 2949–2957.
164. [164] Tan, H.K., Marquez, M., Wong, F., Renner, E.L., Pretransplant type 2 hepatorenal syndrome is associated with persistently impaired renal function after liver transplantation. Transplantation 99 (2015), 1441–1446.
165. [165] Rodriguez, E., Henrique Pereira, G., Sola, E., Elia, C., Barreto, R., Pose, E., et al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transpl 21 (2015), 1347–1354.
166. [166] Sommerer, C., Scharf, M., Seitz, C., Millonig, G., Seitz, H.K., Zeier, M., et al. Assessment of renal allograft fibrosis by transient elastography. Transpl Int 26 (2013), 545–551.
167. [167] Grenier, N., Poulain, S., Lepreux, S., Gennisson, J.L., Dallaudiere, B., Lebras, Y., et al. Quantitative elastography of renal transplants using supersonic shear imaging: a pilot study. Eur Radiol 22 (2012), 2138–2146.
168. [168] Stevens, L.A., Coresh, J., Schmid, C.H., Feldman, H.I., Froissart, M., Kusek, J., et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51 (2008), 395–406.